

## Datasheet: PHP105

**BATCH NUMBER 169756**

<b>Description:</b>	RECOMBINANT HUMAN FGF BASIC
<b>Name:</b>	FGF BASIC
<b>Other names:</b>	FGF2
<b>Format:</b>	Rec. Protein
<b>Product Type:</b>	Recombinant Protein
<b>Quantity:</b>	50 µg

### Product Details

#### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			0.2 - 0.4 ng/well
Western Blotting	▪			1.5 - 3.0 ng/lane
Functional Assays	▪			0.1 - 10 ng/ml

Where this protein has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the protein for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Human
<b>Product Form</b>	Purified recombinant protein expressed in <i>E. coli</i> - lyophilized
<b>Reconstitution</b>	Reconstitute with 0.5 ml Tris (5mM, pH7.6). Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution. Further dilutions may be prepared in a buffer containing a carrier protein (eg 0.1% BSA).
<b>Source</b>	E.coli
<b>Buffer Solution</b>	TRIS buffered saline.
<b>Preservative Stabilisers</b>	None present
<b>Carrier Free</b>	Yes

<b>Endotoxin Level</b>	< 0.1 ng/ug
<b>Approx. Protein Concentrations</b>	Total protein concentration 0.1 mg/ml after reconstitution.
<b>External Database Links</b>	<p><b>UniProt:</b>  <a href="#">P09038</a>    <a href="#">Related reagents</a></p> <p><b>Entrez Gene:</b>  <a href="#">2247</a>    FGF2    <a href="#">Related reagents</a></p>
<b>Synonyms</b>	FGFB
<b>Product Information</b>	<p><b>Recombinant Human FGF basic</b> represents the C-terminal portion of human fibroblast growth factor 2 (A<sup>135</sup> - S<sup>288</sup>).</p> <p>Fibroblast growth factor basic (FGF basic), also known as FGF 2, is a heparin binding growth factor which has stimulatory activity on a range of cells of mesenchymal, neuroectodermal and endothelial origin.</p> <p>Note: FGF basic is sensitive to acidic conditions.</p>
<b>Protein Molecular Weight</b>	17.2 kD (154 amino acid sequence)
<b>Activity</b>	Determined by a cell proliferation assay using Balb/c 3T3 cells. The expected ED <sub>50</sub> is ≤ 0.1 ng/ml, corresponding to a specific activity of ≥ 1 x 10 <sup>7</sup> units/mg.
<b>Purity</b>	>95% by SDS PAGE and HPLC analysis
<b>ELISA</b>	This product may be used as a standard for ELISA applications with either <a href="#">AHP1038</a> or <a href="#">AHP1038B</a> .
<b>Western Blotting</b>	This product may be used as the positive control for Western Blot applications with either <a href="#">AHP1038</a> or <a href="#">AHP1038B</a> .
<b>References</b>	<ol style="list-style-type: none"> <li>1. Svendsen, C.N. <i>et al.</i> (1997) Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. <a href="#">Exp Neurol. 148: 135-46.</a></li> <li>2. Dimitrellos, V. <i>et al.</i> (2003) Capillary electrophoresis and enzyme solid phase assay for examining the purity of a synthetic heparin proteoglycan-like conjugate and identifying binding to basic fibroblast growth factor. <a href="#">Biomed Chromatogr. 17 (1): 42-7.</a></li> <li>3. Kim, T.H. <i>et al.</i> (2005) Recombinant human prothrombin kringle-2 induces bovine capillary endothelial cell cycle arrest at G0-G1 phase through inhibition of cyclin D1/CDK4 complex: modulation of reactive oxygen species generation and up-regulation of cyclin-dependent kinase inhibitors. <a href="#">Angiogenesis. 8: 307-14.</a></li> <li>4. van Beuningen, HM <i>et al.</i> (2014) Inhibition of TAK1 and/or JAK can rescue impaired chondrogenic differentiation of human mesenchymal stem cells in osteoarthritis-like</li> </ol>

- conditions. [Tissue Eng Part A. 20 \(15-16\): 2243-52.](#)
5. Pleumeekers, M.M. *et al.* (2014) The *in vitro* and *in vivo* capacity of culture-expanded human cells from several sources encapsulated in alginate to form cartilage. [Eur Cell Mater. 27: 264-80.](#)
  6. Narcisi R *et al.* (2015) Long-term expansion, enhanced chondrogenic potential, and suppression of endochondral ossification of adult human MSCs via WNT signaling modulation. [Stem Cell Reports. 4 \(3\): 459-72.](#)
  7. Quang Le, B. *et al.* (2015) High-Throughput Screening Assay for the Identification of Compounds Enhancing Collagenous Extracellular Matrix Production by ATDC5 Cells. [Tissue Eng Part C Methods. 21 \(7\): 726-36.](#)
  8. Willems, N. *et al.* (2015) Intradiscal application of rhBMP-7 does not induce regeneration in a canine model of spontaneous intervertebral disc degeneration. [Arthritis Res Ther. 17: 137.](#)
  9. Pleumeekers, M.M. *et al.* (2015) Cartilage Regeneration in the Head and Neck Area: Combination of Ear or Nasal Chondrocytes and Mesenchymal Stem Cells Improves Cartilage Production. [Plast Reconstr Surg. 136 \(6\): 762e-774e.](#)
  10. Lolli, A. *et al.* (2016) Silencing of Antichondrogenic MicroRNA-221 in Human Mesenchymal Stem Cells Promotes Cartilage Repair *In Vivo.* [Stem Cells. 34 \(7\): 1801-11.](#)
  11. Cleary, M.A. *et al.* (2016) Expression of CD105 on expanded mesenchymal stem cells does not predict their chondrogenic potential. [Osteoarthritis Cartilage. 24 \(5\): 868-72.](#)
  12. Grotenhuis, N. *et al.* (2016) Biomaterials Influence Macrophage-Mesenchymal Stem Cell Interaction *In Vitro.* [Tissue Eng Part A. 22 \(17-18\): 1098-107.](#)
  13. Kroon, L.M.G. *et al.* (2017) Activin and Nodal Are Not Suitable Alternatives to TGF $\beta$  for Chondrogenic Differentiation of Mesenchymal Stem Cells. [Cartilage. 8 \(4\): 432-8.](#)
  14. Rodrigues, A.I. *et al.* (2017) Calcium phosphates and silicon: exploring methods of incorporation. [Biomater Res. 21: 6.](#)
  15. Quang Le, B. *et al.* (2017) An Approach to *In Vitro* Manufacturing of Hypertrophic Cartilage Matrix for Bone Repair. [Bioengineering \(Basel\). 4 \(2\): 35.](#)
  16. Bach, F.C. *et al.* (2017) Link-N: The missing link towards intervertebral disc repair is species-specific. [PLoS One. 12 \(11\): e0187831.](#)
  17. Pleumeekers, M.M. *et al.* (2018) Trophic effects of adipose-tissue-derived and bone-marrow-derived mesenchymal stem cells enhance cartilage generation by chondrocytes in co-culture. [PLoS One. 13 \(2\): e0190744.](#)
  18. Bach, F.C. *et al.* (2019) Hedgehog proteins and parathyroid hormone-related protein are involved in intervertebral disc maturation, degeneration, and calcification. [JOR Spine. 2 \(4\): e1071.](#)
  19. Lolli, A. *et al.* (2019) Hydrogel-based delivery of anti-miR-221 enhances cartilage regeneration by endogenous cells. [J Control Release. 309: 220-30.](#)
  20. Sivasubramanian, K. *et al.* (2019) Cell-surface markers identify tissue resident multipotential stem/stromal cell subsets in synovial intimal and sub-intimal compartments with distinct chondrogenic properties. [Osteoarthritis Cartilage. 27 \(12\): 1831-40.](#)
  21. Vainieri, M.L. *et al.* (2020) Evaluation of biomimetic hyaluronic-based hydrogels with enhanced endogenous cell recruitment and cartilage matrix formation. [Acta Biomater. 101: 293-303.](#)
  22. Khatab, S. *et al.* (2020) MSC encapsulation in alginate microcapsules prolongs survival after intra-articular injection, a longitudinal *in vivo* cell and bead integrity tracking study. [Cell Biol Toxicol. 36 \(6\): 553-570.](#)

23. Narcisi, R. *et al.* (2021) Expansion and Chondrogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stromal Cells. [Methods Mol Biol. 2221: 15-28.](#)
24. Tellegen, A. *et al.* (2021) Intra-Articular Slow-Release Triamcinolone Acetonide from Polyesteramide Microspheres as a Treatment for Osteoarthritis [Pharmaceutics. 13 \(3\): 372.](#)
25. Teunissen, M. *et al.* (2021) The lower *in vitro*. chondrogenic potential of canine adipose tissue-derived mesenchymal stromal cells (MSC) compared to bone marrow-derived MSC is not improved by BMP-2 or BMP-6. [Vet J. 269: 105605.](#)
26. Du, J. *et al.* (2022) Intradiscal injection of human recombinant BMP-4 does not reverse intervertebral disc degeneration induced by nucleotomy in sheep. [J Orthop Translat. 37: 23-36.](#)
27. Basatvat, S. *et al.* (2023) Harmonization and standardization of nucleus pulposus cell extraction and culture methods [JOR SPINE. Jan 10 \[Epub ahead of print\].](#)
28. Schwab, A. 41:42-53. (2023) Modulating design parameters to drive cell invasion into hydrogels for osteochondral tissue formation [J Orthop Translat.](#)
29. Tryfonidou, M. *et al.* (2023) Notochordal cell-derived matrix inhibits MAPK signaling in the degenerative disc environment [European Cells and Materials. 46: 57-90.](#)
30. Kearney, C.M. *et al.* (2022) Treatment Effects of Intra-Articular Allogenic Mesenchymal Stem Cell Secretome in an Equine Model of Joint Inflammation. [Front Vet Sci. 9: 907616.](#)
31. Laagland, L.T. *et al.* (2022) Hyperosmolar expansion medium improves nucleus pulposus cell phenotype. [JOR Spine. 5 \(3\): e1219.](#)

---

**Storage**

Prior to reconstitution store at -20°C. Following reconstitution store at -20°C.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the protein. Should this product contain a precipitate we recommend microcentrifugation before use.

---

**Guarantee**

Guaranteed for 3 months from the date of reconstitution or until the date of expiry, whichever comes first. Please see label for expiry date.

---

**Health And Safety Information**

Material Safety Datasheet documentation #10308 available at: <https://www.bio-rad-antibodies.com/SDS/PHP105>  
10308

---

**Regulatory**

For research purposes only

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://www.bio-rad-antibodies.com/datasheets)

'M433696:241120'

Printed on 20 Nov 2024